產品屬性：

Cas No.: 4219-52-7

別名: N/A

化學名: N/A

分子式: C14H6N2O2S

分子量: 266.27

溶解度: DMSO: < 1 mg/mL (insoluble or slightly soluble)                                                                                                                                                    *NSC745885 is usually formulated as a suspe
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.

Shipping ConditionEvaluation sample solution : ship with blue ice

All other available size: ship with RT , or blue ice upon request

產品描述：

NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers[1][2].NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC50 of NSC745885 is 0.85 μM after 72 hours' treatment[1].NSC745885 (0.5-4 μM; 24   hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner[1].NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells[1].Cell Viability Assay[1]    Cell Line:SAS cells is obtained from a poorly differentiated human squamous cell carcinomaNSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin[1].Animal Model:Eight-week-old NOD/SCID (NOD.CB17 Prkdcscid/J) mice[1][1]. Chen YW, et al.A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo.PLoS One. 2014 Aug 15;9(8):e104703.

[2]. Tang SH, et al. Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo.Oncotarget. 2014 Nov 15;5(21):10342-55.
特別提醒公司產品僅供科研使用